Patents by Inventor Cornelis Van Berkel

Cornelis Van Berkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Future cardiac event biomarkers CCL3, CCL5, and CCL18
    Patent number: 10746745
    Abstract: The present invention relates to the identification of chemokine biomarkers predictive of future acute coronary syndromes including unstable angina pectoris (UAP). The present invention also identifies particular chemokines as potential therapeutic targets for intervention in cardiovascular diseases.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: August 18, 2020
    Assignees: Academisch Ziekenhuis Leiden, Universiteit Leiden
    Inventors: Ericus Anna Leonardus Biessen, Theodorus Josephus Cornelis Van Berkel, Adriaan Otto Kraaijeveld
  • Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
    Patent number: 10736903
    Abstract: Conjugates of an antibody that binds to PSMA with PBD dimers.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: August 11, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
    Patent number: 10722594
    Abstract: Conjugates of an isolated humanized, anti-CD22 antibody with PBD dimers.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: July 28, 2020
    Assignees: ADC THERAPEUTICS S.A., MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, Patricius Hendrikus Cornelis Van Berkel
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 10695433
    Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: June 30, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • COMBINATION THERAPY WITH AN ANTI-PSMA ANTIBODY-DRUG CONJUGATE
    Publication number: 20200129638
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Application
    Filed: April 20, 2018
    Publication date: April 30, 2020
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Jens Wuerthner, John Hartley, Francesca Zammarchi
  • COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE
    Publication number: 20200129637
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Application
    Filed: April 20, 2018
    Publication date: April 30, 2020
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Jens Wuerthner, John Hartley, Francesca Zammarchi
  • Combination therapy with an anti-axl antibody-drug conjugate
    Patent number: 10544223
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: January 28, 2020
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMTIED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Jens Wuerthner, John Hartley, Francesca Zammarchi
  • PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
    Publication number: 20190358342
    Abstract: A conjugate of formula (I): Ab-(DL)p wherein: Ab is an antibody, or an active fragment of an antibody; DL is (II).
    Type: Application
    Filed: February 8, 2018
    Publication date: November 28, 2019
    Inventor: Patricius Hendrikus Cornelis VAN BERKEL
  • HUMANIZED ANTI-AXL ANTIBODIES
    Publication number: 20190352407
    Abstract: The present disclosure relates to humanized anti-Axl antibodies.
    Type: Application
    Filed: April 15, 2016
    Publication date: November 21, 2019
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, DAVID G. WILLIAMS
  • COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE
    Publication number: 20190218291
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Application
    Filed: November 21, 2018
    Publication date: July 18, 2019
    Inventors: Patricius Hendrikus Cornelis VAN BERKEL, Jens WUERTHNER, John HARTLEY, Francesca ZAMMARCHI
  • PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
    Publication number: 20190015524
    Abstract: The present disclosure relates to the use of ADCs comprising anti-CD25 antibodies for in treating disorders characterized by the presence of CD25+ve cells.
    Type: Application
    Filed: November 25, 2015
    Publication date: January 17, 2019
    Applicants: MEDIMMUNE LIMITED, ADC THERAPEUTICS S.A.
    Inventors: JAY MARSHALL FEINGOLD, PATRICIUS HENDRIKUS CORNELIS VAN BERKEL
  • SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES
    Publication number: 20180303953
    Abstract: Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody which binds AXL, and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine and comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 25, 2018
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD
  • PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
    Publication number: 20180250417
    Abstract: Conjugates of an antibody that binds to CD19 with PBD dimers.
    Type: Application
    Filed: February 15, 2018
    Publication date: September 6, 2018
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD
  • PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
    Publication number: 20180193480
    Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.
    Type: Application
    Filed: March 5, 2018
    Publication date: July 12, 2018
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD
  • Humanized anti-Tn-MUC1 antibodies and their conjugates
    Patent number: 10017580
    Abstract: Humanized anti-Tn-MUC1 antibodies and conjugates thereof. Conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to the antibody are described.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: July 10, 2018
    Assignees: ADC Therpeutics S.A., Medimmune Limited
    Inventors: Patricius Henrikus Cornelis Van Berkel, Philip Wilson Howard, David G. Williams
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 10010624
    Abstract: Conjugates of specific PBD dimers with an antibody that binds to PSMA, the antibody comprising a VH domain having the sequence according to any one of SEQ ID NOs. 1, 3, 5, 7, 8, 9, or 10, optionally further comprising a VL domain having the sequence 5 according to any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: July 3, 2018
    Assignee: Medimmune Limited
    Inventors: Philip Wilson Howard, Patricius Hendrikus Cornelis Van Berkel
  • PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES
    Publication number: 20180169258
    Abstract: Conjugates of an isolated humanized, anti-CD22 antibody with PBD dimers.
    Type: Application
    Filed: January 31, 2018
    Publication date: June 21, 2018
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD
  • FUTURE CARDIAC EVENT BIOMARKERS
    Publication number: 20180172703
    Abstract: The present invention relates to the identification of chemokine biomarkers predictive of future acute coronary syndromes including unstable angina pectoris (UAP). The present invention also identifies particular chemokines as potential therapeutic targets for intervention in cardiovascular diseases.
    Type: Application
    Filed: January 11, 2018
    Publication date: June 21, 2018
    Inventors: Ericus Anna Leonardus Biessen, Theodorus Josephus Cornelis Van Berkel, Adriaan Otto Kraaijeveld
  • DIAGNOSTIC TEST INVOLVING ANTI-CD25-ADC
    Publication number: 20180142025
    Abstract: The present disclosure relates to determining the eligibility of subjects for treatment and particularly, although not exclusively, to selecting subjects for treatment with an Antibody Drug Conjugate comprising an anti-CD25 antibody.
    Type: Application
    Filed: November 25, 2015
    Publication date: May 24, 2018
    Inventor: Patricius Henrikus Cornelis VAN BERKEL
  • HUMANIZED ANTI-AXL ANTIBODIES AND THEIR CONJUGATES
    Publication number: 20180127505
    Abstract: The present disclosure relates to humanized anti-Axl antibodies and conjugates thereof. Conjugates comprising pyrroiobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to the antibody are described.
    Type: Application
    Filed: April 15, 2016
    Publication date: May 10, 2018
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD, DAVID G. WILLIAMS